Home Tags Shire

Tag: Shire

Shire CEO Flemming Ornskov

Takeda is closing in on buying Adderall maker Shire for $64 billion in pharma’s biggest deal of the year

Takeda has reached a deal to buy Adderall drugmaker Shire for $64 billion. The deal comes after a handful of rejections from Shire and a short-lived potential for a bidding war between Takeda and Botox-maker Allergan.
Takeda CEO Christophe Weber

Takeda’s considering turning up the heat on its bid for Shire

Shire has already turned down three offers already from the Japanese pharmaceutical company Takeda, including one worth $60 billion.
Shire CEO Flemming Ornskov

A bidding war for the maker of Adderall stalled out after just 4 hours

Shire rejected a $60 billion bid from the Japanese drugmaker Takeda, while Allergan briefly considered getting into the fray on Thursday.

Here’s how the CEO of a $50 billion drugmaker sees tech companies ‘disrupting’ healthcare

Shire CEO Flemming Ornskov told Business Insider that there were certain ways he expected the tech industry to enter the pharma space.

Why the CEO of a $50 billion company thinks you should look to Roger Federer for career inspiration

Business Insider asked Shire CEO Flemming Ornskov for his best career advice.

Here’s what the 59-year-old CEO of a $50 billion healthcare company does to stay fit

Shire CEO Flemming Ornskov thinks routines are very important and tries to swim every day.

The CEO of a $50 billion company explains why big-ticket dealmaking has dropped

Shire CEO Flemming Ornskov said there were a few reasons there aren't many deals right now — but that that won't always be the case.

Here’s what the CEO of a $50 billion drug company wants out of health reform

Shire CEO Flemming Ornskov is concerned about whether the legislation would make changes to how people with existing illnesses get coverage.

The first mega-takeover of 2016 just landed

Shire's $32 billion takeover of Baxalta makes it a leader in the treatment of rare diseases.

The first massive takeover of 2016 is already approaching

A $32 billion cash-and-stock deal for Baxalta could be reached as soon as this week, Bloomberg reports.